Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 6/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | CCR3 | P51677 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMO | Q99835 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7244146 | 0.88 | KDM1A (0.37) | CYP2D6OPRK1SIGMAR1KDM1AGRIN2B | |
| SCHEMBL7251058 | 0.88 | GRIN2B (0.37) | CYP2D6OPRK1SIGMAR1KDM1AGRIN2B | |
| SCHEMBL7245322 | 0.85 | MGLL (0.41) | SIGMAR1GRIN2B | |
| SCHEMBL7250827 | 0.83 | CYP2D6 (0.37) | CYP2D6OPRK1SIGMAR1KDM1AGRIN2B | |
| SCHEMBL7244468 | 0.82 | CCR5 (0.42) | CYP2D6OPRK1KDM1ACCR3CCR2 | |
| SCHEMBL7248514 | 0.82 | DRD2 (0.44) | CYP2D6OPRK1SIGMAR1MCHR1 | |
| SCHEMBL7248955 | 0.80 | HRH3 (0.37) | CYP2D6OPRK1SIGMAR1CCR3MCHR1 | |
| SCHEMBL7250306 | 0.80 | HRH3 (0.37) | CYP2D6OPRK1KDM1AMEN1 | |
| SCHEMBL7251803 | 0.80 | HRH3 (0.41) | CYP2D6OPRK1CCR3KCNH2MEN1 | |
| SCHEMBL7252505 | 0.79 | CYP2D6 (0.41) | CYP2D6OPRK1CCR3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6559162-B2 | Electrophysiological activity | ASTRAZENECA AB (SE) | 2003-05-06 | — | — | US | disclosed |
| US-20020137766-A1 | Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137766-A1 | Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias | KCNH1, KCNH2, KCNH3 | CYP2D6 69/4885OPRK1 3005/4885SIGMAR1 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.